Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AADI Aadi Bioscience	$1.81	$1.84	$1.21 ▼ $3.81	$44.70M	0.68	261,100 shs	70,452 shs
CYBN Cybin	$7.64 -0.4%	$7.65	$4.81 ▼ $13.88	$180.23M	0.68	323,295 shs	299,610 shs
MCRB Seres Therapeutics	$18.99 +0.6%	$13.60	$6.53 ▼ $26.40	$166.26M	2.9	99,948 shs	84,134 shs
NKTX Nkarta	$2.20 -1.8%	$1.99	$1.31 ▼ $6.63	$156.27M	0.72	932,548 shs	374,131 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AADI Aadi Bioscience	+6.47%	+9.70%	-7.18%	+4.02%	+7.74%
CYBN Cybin	+2.95%	+16.21%	-0.90%	-4.84%	+1,978.59%
MCRB Seres Therapeutics	-2.43%	+5.24%	+42.60%	+166.29%	+13.73%
NKTX Nkarta	+1.36%	-0.88%	+1.82%	+23.76%	-58.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AADI Aadi Bioscience	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CYBN Cybin	2.3935 of 5 stars	3.6	0.0	0.0	0.0	1.8	0.8	1.3
MCRB Seres Therapeutics	3.2539 of 5 stars	2.9	1.0	0.0	4.6	2.9	0.8	0.0
NKTX Nkarta	2.1361 of 5 stars	3.5	0.0	0.0	0.0	3.5	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AADI Aadi Bioscience	0.00	N/A	N/A	N/A
CYBN Cybin	3.25	Buy	$85.00	1,012.57% Upside
MCRB Seres Therapeutics	1.75	Reduce	$73.67	287.92% Upside
NKTX Nkarta	3.00	Buy	$13.60	518.18% Upside

Current Analyst Ratings Breakdown

Latest AADI, CYBN, MCRB, and NKTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	NKTX Nkarta	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $12.00
8/13/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
7/8/2025	CYBN Cybin	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$73.00 ➝ $70.00
6/10/2025	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AADI Aadi Bioscience	$25.07M	1.78	N/A	N/A	$4.29 per share	0.42
CYBN Cybin	N/A	N/A	N/A	N/A	$10.83 per share	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	$3.76 per share	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.04 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AADI Aadi Bioscience	-$65.76M	-$2.35	N/A	N/A	N/A	-246.06%	-71.87%	-57.28%	11/4/2025 (Estimated)
CYBN Cybin	-$57.88M	-$4.60	N/A	N/A	N/A	N/A	-37.58%	-36.59%	N/A
MCRB Seres Therapeutics	$140K	-$4.60	N/A	N/A	N/A	N/A	-350.16%	-67.69%	11/12/2025 (Estimated)
NKTX Nkarta	-$108.79M	-$1.48	N/A	N/A	N/A	N/A	-27.74%	-22.38%	11/6/2025 (Estimated)

Latest AADI, CYBN, MCRB, and NKTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	NKTX Nkarta	-$0.37	-$0.31	+$0.06	-$0.31	N/A	N/A
8/6/2025	Q2 2025	MCRB Seres Therapeutics	-$2.72	-$2.27	+$0.45	-$2.27	$11.75 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AADI Aadi Bioscience	N/A	N/A	N/A	N/A	N/A
CYBN Cybin	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AADI Aadi Bioscience	N/A	4.89	4.54
CYBN Cybin	N/A	24.24	24.24
MCRB Seres Therapeutics	N/A	1.57	1.57
NKTX Nkarta	N/A	15.67	15.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AADI Aadi Bioscience	52.08%
CYBN Cybin	17.94%
MCRB Seres Therapeutics	59.34%
NKTX Nkarta	80.54%

Insider Ownership

Company	Insider Ownership
AADI Aadi Bioscience	37.30%
CYBN Cybin	15.00%
MCRB Seres Therapeutics	4.70%
NKTX Nkarta	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AADI Aadi Bioscience	40	24.70 million	15.49 million	Optionable
CYBN Cybin	50	23.59 million	17.96 million	Not Optionable
MCRB Seres Therapeutics	330	8.76 million	8.34 million	Optionable
NKTX Nkarta	140	71.03 million	65.06 million	Optionable

AADI, CYBN, MCRB, and NKTX Headlines

Recent News About These Companies

Nkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of "Buy" by Brokerages

August 26 at 2:08 AM | marketbeat.com

Nkarta (NASDAQ:NKTX) Stock Rating Upgraded by Wall Street Zen

August 19, 2025 | americanbankingnews.com

Equities Analysts Issue Forecasts for Nkarta Q3 Earnings

August 17, 2025 | marketbeat.com

Equities Analysts Set Expectations for Nkarta Q3 Earnings

August 17, 2025 | marketbeat.com

Wall Street Zen Upgrades Nkarta (NASDAQ:NKTX) to "Hold"

August 17, 2025 | marketbeat.com

HC Wainwright Issues Pessimistic Outlook for Nkarta Earnings

August 17, 2025 | americanbankingnews.com

Nkarta (NASDAQ:NKTX) Given New $12.00 Price Target at Stifel Nicolaus

August 16, 2025 | marketbeat.com

Nkarta (NASDAQ:NKTX) Receives Buy Rating from Needham & Company LLC

August 15, 2025 | marketbeat.com

Nkarta price target lowered to $12 from $14 at Stifel

August 15, 2025 | msn.com

Nkarta (NASDAQ:NKTX) Announces Earnings Results, Beats Estimates By $0.06 EPS

August 14, 2025 | marketbeat.com

Nkarta, Inc.: Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

August 13, 2025 | finanznachrichten.de

Nkarta, Inc. Reports Q2 2025 Financial Results

August 12, 2025 | tipranks.com

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

August 12, 2025 | globenewswire.com

Nkarta (NKTX) Expected to Announce Earnings on Tuesday

August 6, 2025 | marketbeat.com

Monaco Asset Management SAM Invests $1.50 Million in Nkarta, Inc. (NASDAQ:NKTX)

July 31, 2025 | marketbeat.com

Nkarta, Inc. (NASDAQ:NKTX) Receives Consensus Recommendation of "Buy" from Analysts

July 30, 2025 | marketbeat.com

Nkarta to Participate in the H.C. Wainwright "HCW@Home" Series

July 23, 2025 | tmcnet.com

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

July 23, 2025 | globenewswire.com

Nkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025

July 22, 2025 | seekingalpha.com

Will Nkarta (NASDAQ:NKTX) Spend Its Cash Wisely?

June 27, 2025 | uk.finance.yahoo.com

Nkarta, Inc. (NKTX) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AADI, CYBN, MCRB, and NKTX Company Descriptions

Aadi Bioscience NASDAQ:AADI

$1.81 0.00 (0.00%)

As of 08/27/2025

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Cybin NYSE:CYBN

$7.64 -0.03 (-0.39%)

Closing price 04:00 PM Eastern

Extended Trading

$7.66 +0.02 (+0.26%)

As of 05:25 PM Eastern

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

Seres Therapeutics NASDAQ:MCRB

$18.99 +0.11 (+0.58%)

Closing price 04:00 PM Eastern

Extended Trading

$18.80 -0.19 (-1.03%)

As of 04:10 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Nkarta NASDAQ:NKTX

$2.20 -0.04 (-1.79%)

Closing price 04:00 PM Eastern

Extended Trading

$2.27 +0.07 (+3.00%)

As of 04:36 PM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time